statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Bitcoin

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Invesco QQQ Trust Series 1

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Allarity Therapeutics halts Phase 2 trial, citing compelling early results and plans for regulatory advancement. CEO Thomas Jensen affirms strategic shift. ALLR shares surge 38%.
read more...

Why Is Nano-Cap Allarity Therapeutics Stock Trading Up On Thursday?

Allarity Therapeutics, Inc. (NASDAQ:ALLR - Free Report) shares are scheduled to reverse split on the morning of Tuesday, April 9th. The 1-20 reverse split was announced on Tuesday, April 9th. The...

Allarity Therapeutics (NASDAQ:ALLR) Shares to Reverse Split on Tuesday, April 9th

Boston (April 4, 2024) Allarity Therapeutics, Inc. ( Allarity or the Company ) (NASDAQ: ALLR), a clinical-stage pharmaceutical company dedicated to developing personalized cancer treatments...

Allarity Therapeutics Announces 1-for-20 Reverse Stock Split

Allarity Therapeutics, Inc. (NASDAQ:ALLR - Get Free Report) saw a significant decrease in short interest in the month of March. As of March 15th, there was short interest totalling 614,300 shares, a...

Allarity Therapeutics, Inc. (NASDAQ:ALLR) Short Interest Down 5.9% in March

Allarity Therapeutics, Inc. (NASDAQ:ALLR - Get Free Report) shares traded down 3.8% on Thursday . The stock traded as low as $0.29 and last traded at $0.30. 351,333 shares were traded during trading...

Allarity Therapeutics (NASDAQ:ALLR)  Shares Down 3.8%

The stenoparib Phase 2 monotherapy trial in advanced, recurrent ovarian cancer continues to show promise, prompting shift in resources to accelerate stenoparib development Further development of...

Allarity Therapeutics Makes Strategic Pivot to Focus Solely on Accelerating Stenoparib Toward Regulatory Approval in Advanced Recurrent Ovarian Cancer

Boston (March 25, 2024) Allarity Therapeutics, Inc. ( Allarity or the Company ) (NASDAQ: ALLR), a clinical-stage pharmaceutical company dedicated to developing personalized cancer treatments...

Allarity Therapeutics Receives Extension from Nasdaq Hearings Panel to Regain Compliance with Listing Rules 5550(a)(2) and 5550(b)(1)

Leadership Changes Led by Appointment of Co-Founder Thomas Jensen as Interim CEO and Jeremy Graff, Ph.D., former Eli Lilly Executive, as Executive AdvisorReduced Net Loss from Operations by 50% and...

Allarity Therapeutics Reports Full Year 2023 Financial Results and Provides a Business Update

Boston (February 28, 2024) Allarity Therapeutics, Inc. ( Allarity or the Company ) (NASDAQ: ALLR), a clinical-stage pharmaceutical company dedicated to developing personalized cancer treatments...

Allarity Therapeutics to Present at Biomarkers 2024

Allarity Therapeutics, Inc. (NASDAQ:ALLR  Get Free Report) saw a significant drop in short interest in the month of December. As of December 31st, there was short interest totalling 673,000...

Allarity Therapeutics, Inc. (NASDAQ:ALLR) Sees Significant Drop in Short Interest

Allarity Therapeutics, Inc. engages in the development of drugs for personalized treatment of cancer guided by its proprietary Drug Response Predictor (DRP) technology. The company operates in two geographic areas: Denmark and the United States. The company was founded on April 4, 2021 and is headquartered in Boston, MA.

Volume	7.56M
52-Wk High	$366.40
52-Wk Low	$0.95

ALLR Allarity Therapeutics Inc

About

Feed

News

Fundamentals